Technology
Scientific Approach
Scientific Approach

Leveraging novel technologies
uniquely suited to the eye

ATSENA THERAPEUTICS’ next-generation adeno-associated virus (AAV) technologies – laterally spreading capsids, dual vectors, and intravitreal capsids – are designed to overcome the limitations of current gene therapies and address the significant unmet need in inherited retinal diseases.

Our technologies are uniquely suited for the prevention or reversal of blindness. We utilize an AAV capsid, payload and delivery approach that is engineered for each disease, and our AAV vectors are designed for delivery via subretinal or intravitreal injection.

Laterally Spreading Capsids

Our laterally spreading capsid AAV.SPR ensures gene delivery to large areas of the retina and safe delivery to the fovea.

LEARN MORE

Dual Vector Technology

Our dual vectors are constructed to deliver target genetic payloads for genetic mutations that have been untreatable with a single AAV vector.

LEARN MORE

Intravitreal Capsids

Our novel AAV capsids for intravitreal injection are optimized and selected to avoid detection by the patient’s immune system.

LEARN MORE

accessibility optionsAccessibility
Text Size
A
A